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Introduction
The Bacterial Microarray Group at St George’s
Hospital Medical School (BµG@S; http://bugs.
sghms.ac.uk) has been funded by The Wellcome
Trust as part of the Resources for Functional
Genomics Initiative. A 5 year programme grant
entitled ‘A Multi-Collaborative Microbial Pathogen
Microarray Facility’ was awarded to Dr Philip
Butcher and Joseph Mangan (St. George’s Hospital
Medical School), Professor Brendan Wren (London
School of Hygiene and Tropical Medicine), Pro-
fessor Neil Stoker (Royal Veterinary College, Lon-
don) and Dr Keith Vass (Beatson Institute/Glasgow
University). The aim of this funding is to enable
a community of collaborating researchers with a
common interest in bacterial pathogenesis to have
rapid, flexible and cost-effective access to current
microarray technology. Rather than each individ-
ual group having to invest in the equipment and the
lengthy learning and optimization process involved
in microarray set-up, the aim was to centralize the
expertise within one group that would then be made
freely available to collaborating groups as a func-
tional genomics resource. The project was funded
to produce whole-genome DNA microarrays for
12 bacterial pathogens within 2 years and provide
training and support in the use of the arrays over a
period of 5 years. This article provides an overview
of the project organization, the technology and sup-
port involved in producing and using the microar-
rays, future developments and a summary of the
progress to date.
Project structure
The ethos behind the project was to create a
collaborative network of scientists who would all
interact with both the central microarray facil-
ity (BµG@S) and other groups within the net-
work. Rather than the arrays being produced
on a ‘commercial’ basis and simply handed out
to ‘customers’, the aim was to create working
collaborations in which BµG@S scientists and
pathogen researchers would pool together their
respective areas of expertise to advance the area
of bacterial functional genomics rapidly and in
a more focused manner. The collaborative net-
work currently consists of over 30 academic
research groups, including those interested in par-
ticular bacterial pathogens, aspects of pathogenesis,
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genome biology, bioinformatics or the analysis and
management of microarray data.
For a large collaborative project of this nature,
the organizational structure is important to ensure
that the communication between groups is clear and
that the process is transparent and fair for all users.
The BµG@S group form the central hub of this
network and has scientists funded to design and
construct the arrays, provide training to users, sup-
ply informatics support in the form of databases
and analysis tools and also give general administra-
tive support to the project. Around this core facility
the user groups, clustered by bacterial pathogen and
array, provide expert knowledge of each pathogen
to aid the design process and also coordinate the
use of the arrays. The user community decide the
best use of the arrays available, rather than the cen-
tral facility. Overseeing the whole process is the
steering committee, which is primarily composed
of independent scientists and the grant holders, as
well as representatives from the BµG@S group and
The Wellcome Trust. The purpose of the steering
committee is to provide independent and impar-
tial advice, monitor progress and deal with any
issues arising from the project. The collaborating
groups form a network around this central struc-
ture of BµG@S, user groups and steering com-
mittee, interacting not only with BµG@S but also
with each other. New research groups wishing to
access the BµG@S arrays do so on the basis of
agreed academic collaboration with one or more
of the existing pathogen user-groups. Collaborating
groups include biologists using the arrays in their
research, genome sequencing centres, such as The
Wellcome Trust Sanger Institute, groups involved
in data analysis and other independent research-
based array facilities.
Microarray design
The microarrays produced by our group are of
the spotted PCR product type, generally based
on protocols originally developed by the Brown
lab in Stanford University (http://cmgm.stanford.
edu/pbrown/) and used by many groups [2,3]. The
first stage in the process is the design of the
microarray. The basic requirement for a microar-
ray intended for a global genome-wide analysis is
to have each gene in the genome represented on the
array. The starting point for any array is commonly
an annotated genome sequence that provides a
defined reference in terms of gene predictions and
annotations. By working closely with the user
groups for each pathogen, any important biolog-
ical features, identified from either the genome
sequence or expert knowledge of the pathogen, can
be incorporated in the array design. For example,
information about unusual gene families or hyper-
variable genes can be accounted for in the design
process to ensure that the maximum amount of
information can be gained for each gene. The inclu-
sion of the user community at the design stage,
combined with the flexibility that is inherent with
in-house array production, enables the arrays to
be customised to meet particular needs. Additional
elements may be added to the array to represent
genes not present in the sequenced strain, possi-
bly identified in other strains by methods such as
subtractive hybridization, or alternatively to include
elements to represent related genes from other bac-
terial species that are considered useful.
Increasingly, there are genome sequences avail-
able for numerous strains of a particular bacterial
species, or even closely related species. It is there-
fore important that the array design should cover
all available genome sequences of a species, so that
composite arrays are constructed, either at the out-
set in the initial design or at a subsequent stage
in the continuing development and evolution of an
array, as more sequences become available. The
majority of genes are common to all strains and
have a high degree of homology between strains;
this means that an element on the array which rep-
resents a gene in one strain will also represent
the homologous gene in other strains. Therefore,
the production of a composite array would require
an element to represent each of the genes com-
mon to all strains plus the strain-specific genes
and we have developed methods to achieve this
gene selection.
The spotted PCR product approach employed
means that the overall objective of the design pro-
cess is to generate gene-specific primer pairs to
enable amplification of a PCR product to repre-
sent each of the genes selected for inclusion on
the array. Software has been developed so that,
essentially, a whole-genome sequence is input at
the start and the primer sequences are output at
the end. The basic stages in this process are to
extract the gene sequences and systematic iden-
tifiers from an annotated genome sequence file,
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design several possible PCR products for each gene
using Primer3 [4] and then select the most suit-
able PCR product to represent each gene. The PCR
product selection is important, as it is primarily
based on BLAST [1] analysis of the potential PCR
product sequences against the gene sequences, and
thus highlights any likely cross-hybridization by
non-target genes. Ideally, the PCR product selected
should be unique to the target gene, but if this is
not possible it should have the minimum amount
of cross-hybridization to the other non-target genes.
This selection approach helps maintain data clarity
by ensuring gene-specific signal for the maximum
number of genes.
Microarray construction
Following the design stage, the next step in the
process is the generation of the PCR products that
will form the elements on the array. The oligonu-
cleotide primer pairs are supplied in a 96-well for-
mat compatible with the robotics used for PCR.
All liquid handling and PCR cycling for genera-
tion of the PCR products are conducted using a
RoboAmp 4200 (MWG Biotech) that incorporates
a non-cross-contamination design, so that only a
single well is open at any one time during the
process. Whilst around 90–95% of the PCR prod-
ucts are obtained at the first attempt, there then
follows a process to complete all the PCR prod-
ucts. This involves repeating reactions, modifying
reaction conditions and possibly resynthesizing the
oligonucleotide primers. The PCR products are all
verified by agarose gel electrophoresis to ensure
that a single product of the correct size is obtained
and further verification is achieved by sequenc-
ing 5% of the PCR products. Clearly, it would be
favourable to sequence verify all products, although
this would substantially add to the cost of construc-
tion. However, an aliquot of the PCR product that
forms the array element is retained, so that users
can verify the sequence of the element at a later
date to validate any interesting results, thus fur-
thering the sequence verification of the array.
Having successfully completed all the PCR reac-
tions, there then follows the preparation of the
PCR products for printing the array. Purifica-
tion and concentration of the PCR products is
achieved by precipitating and washing an aliquot
of the PCR reaction and resuspending in a reduced
volume of 50% DMSO for printing. The PCR
products are transferred to 384-well plates for print-
ing and spotted at high density on poly-L-lysine-
coated glass microscope slides, using a MicroGridII
(BioRobotics) arraying robot. The capacity of the
robot allows it to print to a maximum of 108
glass microscope slides from a total of 24 384-well
plates. Split-pin technology used in the arraying
robot allows a spot to be deposited on a total of
108 slides from a single visit to the PCR products,
generally producing spot size of 150–180 µm. To
give some appreciation of the scale, a microarray
for a bacterial genome is often printed in duplicate
in an area of 20 × 20 mm. In addition to elements
that represent the bacterial genome, a number of
control elements are also spotted on to the array.
Typical controls include bacterial ribosomal RNA
genes as a positive control, human genes as a neg-
ative control or for use with spiking experiments,
controls to check for carry-over of samples during
printing and also fluorescently labelled oligonu-
cleotides that act as orientation markers or ‘landing
lights’ on the array.
The quality of the printed arrays is assessed in
a number of ways before they are used experi-
mentally. Scanning a sample of the arrays directly
after printing gives some indication that the array-
ing has proceeded successfully, highlighting any
gross failures of the pins or spotting artefacts. After
the slides have been post-print processed, under-
taken to attach the DNA to the slides and block
any non-specific binding sites, the DNA on the
arrays may be stained with a fluorescent dye or test
hybridizations performed to check that the DNA is
still present and attached to the arrays and also con-
firm the absence of any spots due to pin ‘misfiring’
during printing.
Application of microarrays
The finished microarrays are then made available
to the pathogen user groups for use in their
experiments. The arrays produced present a limited
resource and so the user groups for a particular
pathogen ensure that the best use is made of
the arrays, achieved by prioritizing the usage and
avoiding unnecessary duplication of experiments.
Rather than having competing groups within the
multi-collaborative network attempting to perform
identical experiments, the aim is to encourage
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new collaborations that address common goals.
The other conference reviews presented in this
issue give a useful overview of the widespread
applications that the current arrays are being used
for in the investigation of the various aspects of
bacterial pathogen biology.
Another strategy to ensure that users make the
best use of the arrays from the start is tackled by
the provision of training courses by BµG@S. The
aim of the training is for users to generate good
quality data from the outset, rather than having
to waste arrays and time developing or optimiz-
ing protocols. The training encompasses hands-on
instruction in hybridization protocols, image and
data analysis software, as well as consideration of
sample preparation and experimental design. The
idea is for new users to gain full benefit from
the expertise built up within the BµG@S group
over a period of time, so the progress of indi-
vidual projects is faster. By complementing the
array expertise within the BµG@S team with the
pathogen expertise of the users, the benefits of
this multi-collaborative approach are evident. The
two-way relationship of the users with BµG@S is
extremely useful, as it allows the dissemination of
new ideas and techniques throughout the whole net-
work of researchers.
Future developments
Whilst the priority of the project remains to pro-
vide microarrays based on the robust and estab-
lished methods described previously, there is also
the need to investigate and evaluate develop-
ing array technologies. There has been a dra-
matic increase in the availability of new prod-
ucts, reagents and approaches within the past year;
some may offer clear advantages over the cur-
rent methods or technologies, whereas others may
not. There remains the balance between continuing
with current methods that work reliably and cost-
effectively and considering possibly improved but
unproven approaches.
As many groups have now progressed to the
stage of generating good quality array data, the
problem of data management and analysis presents
the next challenge. Whilst basic training and sup-
port is provided by BµG@S in the use of soft-
ware such as GeneSpring (Silicon Genetics) for
data analysis and visualization, there is the need to
develop more customized analysis approaches and
tools. Through collaborations with groups that have
an interest in developing methods for microarray
data analysis (see Wernisch, p. 372 and Wolken-
hauer et al., p. 375), such tools will be estab-
lished. The ultimate aim is to integrate the anal-
ysis approaches developed by these groups into a
database (see Witney and Hinds, p. 369) that will
allow users to gain access to array information,
experimental data and analysis tools on a com-
mon platform.
Current progress
At this point in the project whole genome arrays
have been completed for Campylobacter jejuni,
Mycobacterium tuberculosis, Haemophilus influen-
zae and Yersinia pestis, as well as arrays for 500
selected genes in Streptococcus pneumoniae and
the plasmid genes of Salmonella typhi and Yersinia
pestis. Each of the arrays undertaken have ben-
efited from the ability to generate custom arrays
that can be modified to a particular requirement
determined by the users. For example, both the H.
influenzae array and the latest version of the C.
jejuni array include additional genes not present in
the sequenced strain, discovered either in sequence
databases or by experimental investigation, mak-
ing the arrays more inclusive for a greater number
of strains. It should be acknowledged that whilst
The Wellcome Trust have funded the majority of
the arrays produced and planned within the project,
there has also been external funding from collabo-
rators, which is detailed in the acknowledgements.
Whole genome arrays currently in progress,
either in the design or construction stage, are for
Streptococcus pneumoniae, Staphylococcus aureus
and Neisseria meningitidis. The remaining microar-
rays outstanding under the current funding are for
Bordetella pertussis, Clostridium difficile, Chlamy-
dia spp., Helicobacter pylori, Listeria monocyto-
genes and Mycobacterium spp., which are planned
for completion within the next 18 months.
Summary
This report has outlined the approach taken by the
BµG@S group in generating whole-genome DNA
microarrays for a number of bacterial pathogens.
Copyright  2002 John Wiley & Sons, Ltd. Comp Funct Genom 2002; 3: 333–337.
Microarrays for microbes 337
As more of these ‘big biology’ projects are
funded, it is important to recognize the require-
ment to underpin these with the appropriate orga-
nizational framework to ensure effective access
by the academic research community. BµG@S as
a multi-collaborative resource for bacterial func-
tional genomics provides one approach towards
these goals.
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